Vasomotor Symptoms

Global Vasomotor Symptoms Market to Reach US$5.5 Billion by 2030

The global market for Vasomotor Symptoms estimated at US$3.9 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Estrogen Therapy, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Progesterone Therapy segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.5% CAGR

The Vasomotor Symptoms market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Vasomotor Symptoms Market - Key Trends & Drivers Summarized

Why Are Vasomotor Symptoms Garnering Greater Clinical and Pharmaceutical Attention Today?
Vasomotor symptoms (VMS), primarily characterized by hot flashes and night sweats, are among the most prevalent and disruptive manifestations of menopause. Affecting up to 80% of perimenopausal and postmenopausal women globally, these symptoms have traditionally been underdiagnosed and under-addressed in clinical settings. However, recent years have witnessed a growing medical consensus on the need to treat VMS not merely as a discomfort but as a condition with significant impacts on sleep, cardiovascular function, and quality of life. This paradigm shift is driving increased demand for therapeutic options across multiple drug classes and delivery formats.

While hormone replacement therapy (HRT) remains the gold standard in many cases, its use is often limited due to risks associated with breast cancer, thromboembolism, and cardiovascular disease in some patient groups. As a result, there is rising demand for non-hormonal interventions including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and more recently, neurokinin-3 (NK3) receptor antagonists. This therapeutic expansion is accompanied by heightened screening, awareness campaigns, and regulatory approvals that together are broadening the VMS treatment landscape, particularly in North America and Europe.

How Is Innovation in Drug Development and Delivery Enhancing VMS Management?
The pharmaceutical innovation pipeline for vasomotor symptoms is being reshaped by a surge in interest in non-hormonal and targeted therapies. The approval of fezolinetant, an oral NK3 receptor antagonist, marks a significant milestone as it directly targets thermoregulatory dysfunction believed to cause VMS. Its market entry has catalyzed development in similar classes by other pharmaceutical players, with multiple NK3 antagonists currently in Phase II and III trials. These innovations are pivotal for patients contraindicated for hormone therapy and may define a new standard of care in VMS treatment.

Drug delivery formats are also evolving to improve adherence and patient preference. Transdermal patches, vaginal rings, and topical sprays are gaining market share alongside traditional oral pills, addressing both systemic and localized symptoms. Complementary to prescription-based solutions, the over-the-counter (OTC) and nutraceutical segments are seeing robust activity, particularly in botanicals such as black cohosh, red clover, and soy isoflavones, though clinical efficacy remains mixed. Additionally, digital therapeutics including CBT-based apps targeting sleep and mood disturbances from VMS are emerging as adjunct tools, especially in markets with high digital literacy.

Where Is Market Adoption Accelerating and What Patient Segments Are Driving Growth?
The most mature markets for vasomotor symptom therapies are in the U.S., Canada, and several European nations where menopause awareness and healthcare access are relatively high. In the U.S., direct-to-consumer (DTC) platforms and femtech companies are aggressively pushing personalized menopause care, including VMS-specific solutions bundled with virtual consultations, remote prescriptions, and lab testing. The commercial success of brands targeting menopausal women with discrete and dignified support services is reinforcing demand in adjacent categories such as sleep aids, mental health, and sexual wellness.

In Asia-Pacific and Latin America, the VMS market is gaining traction as demographic transitions increase the menopausal population, and stigma around menopause begins to erode. Urban centers in Japan, South Korea, and China are emerging as high-growth hubs where Western therapies are being adapted to local preferences. Additionally, a younger demographic of health-conscious perimenopausal women aged 40-50 is emerging as a key consumer group, particularly in private healthcare systems. These women are seeking early interventions, lifestyle-aligned treatment options, and holistic approaches to managing hormonal changes.

What Forces Are Powering the Expansion of the Global VMS Market?
The growth in the vasomotor symptoms market is driven by several factors, including increasing female life expectancy, greater openness to menopause-related healthcare, and a rapidly expanding product pipeline. As women spend a third of their lives in postmenopause, the demand for long-term, safe, and effective treatments is growing. Enhanced awareness campaigns, employer-sponsored wellness programs, and the destigmatization of menopause across social platforms are all encouraging treatment-seeking behavior. Health insurers and providers are also beginning to integrate menopause care into broader women’s health services.

Pharmaceutical innovation-especially in non-hormonal drug classes-remains a critical growth driver. The entry of blockbuster therapies such as fezolinetant has catalyzed investment from mid- and large-cap pharmaceutical companies. Regulatory bodies are increasingly receptive to fast-track approvals given the previously unmet needs in this segment. The rise of femtech and digital therapeutics is adding further momentum, offering scalable and personalized solutions that make VMS care more accessible. Collectively, these shifts point toward a significant expansion of the VMS market globally, with both prescription and consumer wellness pathways contributing to its long-term trajectory.

SCOPE OF STUDY:

The report analyzes the Vasomotor Symptoms market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy Type (Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy, Other Therapy Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores); End-User (Hospitals & Clinics End-User, Specialty Centers End-User, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Astellas Pharma
• Bayer AG
• Biogen (partnering)
• Bionovo
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Gedeon Richter
• GlaxoSmithKline (GSK)
• HRA Pharma
• Johnson & Johnson
• Merck & Co.
• NeRRe Therapeutics
• NeRRe Therapeutics (dual)
• Noema Pharma
• Noven Pharmaceuticals
• Novo Nordisk
• Ogeda (now Astellas)
• Pfizer (Duavee)
• Pfizer Inc.
• Shionogi & Co.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more